India CDSCO Proposes New Medical Device Import Rules for Hospitals (2026)

India CDSCO Proposes New Medical Device Import Rules for Hospitals (2026)

India's drug regulator, the CDSCO, has proposed a new framework to allow hospitals to directly import a list of 80 high-end medical devices, such as MRI and CT scanners. This episode explores the potential policy shift, which aims to bypass the traditional licensed importer route to speed up access to advanced technology. We cover the implications for international manufacturers, the patient safety and post-market surveillance concerns raised by domestic industry, and the practical steps regulatory and quality teams should take now to prepare for this change. Key Questions: - What is India's CDSCO proposing for high-end medical device imports as of June 2026? - Which types of devices like MRI and CT scanners are on the proposed direct import list? - How could this policy change the market access strategy for international manufacturers in India? - What are the primary patient safety concerns with allowing hospitals to import devices directly? - Why is post-market surveillance a critical challenge in this proposed framework? - How does this proposal differ from the existing Medical Device Rules, 2017? - What are the potential benefits that are driving this proposed policy change? - What practical actions should regulatory and quality teams take during the stakeholder consultation phase? Sources: - https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/plan-in-the-works-to-let-hospitals-import-med-equipment-directly/articleshow/111107931.cms - https://whalesbook.com/news/india-proposes-direct-import-path-for-high-end-medical-gear - https://www.livemint.com/industry/govt-plans-to-allow-hospitals-to-directly-import-high-end-medical-equipment-11718854992523.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like those emerging in India. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure compliance. By combining in-country expertise with advanced AI technology, we streamline the registration process and help you monitor critical regulatory changes. To learn how we can help you access over 30 global markets faster, visit us at https://pureglobal.com, email info@pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

Health Canada's 2026 Hyperbaric Chamber Warning: Compliance for Unlicensed Devices

Health Canada issued a public advisory on June 16, 2026, warning that unauthorized soft-shelled hyperbaric chambers are illegal to sell, import, or advertise in Canada. This episode breaks down the specific health risks identified, the regulatory status of these devices, and the enforcement actions being taken. We provide practical compliance steps for manufacturers and distributors of wellness devices to ensure their products meet Canadian regulations and avoid similar enforcement actions. Key Questions: - What specific risks did Health Canada identify with soft-shelled hyperbaric chambers? - Why are these devices classified as illegal Class II medical devices in Canada? - What enforcement actions can manufacturers and distributors expect from Health Canada? - How does this advisory impact the broader 'wellness' device industry? - What are the unproven therapeutic claims associated with these unlicensed devices? - How can companies audit their product portfolios for compliance with Health Canada's regulations? - What steps should importers take to verify the licensing status of products from their partners? - How can you ensure your marketing claims do not trigger regulatory scrutiny? Sources: - https://www.canada.ca/en/health-canada/news/2026/06/public-advisory---unauthorized-soft-shelled-hyperbaric-chambers-may-pose-serious-health-risks.html - https://www.cp24.com/news/this-medical-device-may-cause-serious-health-risks-and-even-death-health-canada-warns-1.7000000 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 countries, including Canada. We use advanced AI to streamline compliance and ensure your products, from initial classification to post-market surveillance, meet all requirements. Whether you're a startup or a multinational, we can help you navigate complex regulatory landscapes like Health Canada's requirements and avoid costly compliance issues. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

Health Canada MDEL Regulations 2026: What Importers and Foreign Manufacturers Need to Know

Health Canada has finalized amended regulations for its Medical Device Establishment Licence (MDEL) framework, which come into force on December 14, 2026. This episode breaks down the critical changes, including the removal of the MDEL requirement for foreign distributors who sell through a licensed Canadian importer and the new obligation for Canadian MDEL holders to provide a complete list of their suppliers. We explore the practical impact on foreign manufacturers, Canadian importers, and distributors, and outline key steps to ensure compliance before the deadline. Key Questions: - What are the key changes in Health Canada's updated MDEL framework? - When do the new MDEL regulations come into force? - Do foreign distributors still need an MDEL to sell medical devices in Canada? - What new information must Canadian MDEL holders provide to Health Canada? - How does this change affect the responsibilities of Canadian importers? - What is the impact on foreign manufacturers selling into the Canadian market? - What practical steps should my company take to prepare for the December 14, 2026 deadline? - How will the new supplier list requirement enhance supply chain traceability? - Does my company need to update its distribution agreements for the Canadian market? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/bulletins/modernize-medical-device-establishment-licensing-phase-2.html - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-medical-device-establishment-licensing-gui-0016-effective-december-14-2026/other-regulatory-requirements.html - https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/directives-guidance-documents-policies/guidance-medical-device-establishment-licensing-gui-0016-effective-december-14-2026/contact-us.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex market access requirements. For companies impacted by Health Canada's new MDEL rules, we offer expert regulatory strategy, act as a local representative, and help update quality systems to ensure seamless compliance. Our technology-driven approach streamlines technical dossier management and submission, helping you access over 30 global markets faster. Learn more about our free AI tools and global device database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com to discuss your market access goals.

FDA AI Software Classification 2026: Class II and PCCP Rules for Imaging Devices

On June 17, 2026, the US FDA finalized a new Class II classification for radiological machine learning-based quantitative imaging software. This episode breaks down the new rule, explaining how the inclusion of a Predetermined Change Control Plan (PCCP) creates a more streamlined process for future algorithm updates. We detail the specific device types affected and the special controls manufacturers must now implement, offering practical steps for regulatory and quality teams to adapt their strategies. Key Questions: - What is the new FDA classification for AI/ML imaging software announced on June 17, 2026? - How does a Predetermined Change Control Plan (PCCP) streamline post-market updates? - What specific device types fall under this new Class II regulation? - What are the "special controls" manufacturers must now implement? - How does this change affect the regulatory strategy for AI-based medical devices? - What steps should your QMS team take to prepare for a PCCP submission? - Are there specific labeling requirements under this new final order? - How can companies leverage this new pathway for faster market access? Sources: - https://www.federalregister.gov/documents/2026/06/17/2026-12166/medical-devices-radiology-devices-classification-of-the-radiological-machine-learning-based - https://www.fda.gov/about-fda/cdrh-new-news-and-updates/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like the FDA's new AI software classification. Our experts develop efficient regulatory strategies, create robust technical dossiers, and manage submissions to authorities worldwide. By combining local expertise with advanced AI tools, we streamline global market access, helping you get your products to patients faster. For support with your FDA submission, PCCP development, or global expansion, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

Brazil ANVISA SaMD Regulation Update: Preparing for Changes to RDC 657/2022

Brazil's health agency, ANVISA, has announced its 2026-2027 regulatory agenda, which includes a significant revision to the rules for Software as a Medical Device (SaMD), RDC 657/2022. This episode explores the reasons for the update, the potential changes manufacturers can expect regarding AI/ML validation and cybersecurity, and the practical steps regulatory affairs and quality teams should take now to prepare for the upcoming public consultations and new requirements. Key Questions: - What are ANVISA's key regulatory priorities for 2026-2027? - Why is Brazil planning to update its SaMD regulation, RDC 657/2022? - Which types of SaMD manufacturers will be most affected by these changes? - What new requirements related to AI/ML and cybersecurity can we expect in the revised rule? - How will the new rules likely align with international standards from the IMDRF? - When can companies expect public consultations on the draft regulation? - What practical steps should regulatory teams take now to prepare? - How can a proactive gap analysis help in preparing for the new ANVISA rules? Sources: - https://www.emergobyul.com/blog/2026/01/brazil-anvisa-announces-priorities-2026-2027-year - https://www.pure-global.com/post/anvisa-s-international-cooperation-and-regulatory-convergence-are-reshaping-brazil-s-medical-device-market - https://www.mattosfilho.com.br/en/unico/anvisa-approves-new-regulatory-framework-for-software-as-a-medical-device/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex market access challenges like ANVISA's upcoming SaMD regulation changes. Our local experts in Brazil can act as your official representative, develop a clear regulatory strategy, and use advanced AI to compile and manage your technical submissions efficiently. We monitor regulatory changes in real-time to ensure you are always prepared. Whether you are a startup or a multinational, we streamline your path to market in Brazil and over 30 other countries. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai to learn more.